Trump DL - Search Results

1

Carmustine and streptozocin in refractory melanoma: an attempt at modulation of O-alkylguanine-DNA-alkyltransferase.

Smith DC, Gerson SL, Liu L, Donnelly S, Day R, Trump DL, Kirkwood JM. Smith DC, et al. Among authors: trump dl. Clin Cancer Res. 1996 Jul;2(7):1129-34. Clin Cancer Res. 1996. PMID: 9816278 Clinical Trial.

2

Megestrol acetate in the treatment of hormone refractory prostate cancer.

Osborn JL, Smith DC, Trump DL. Osborn JL, et al. Among authors: trump dl. Am J Clin Oncol. 1997 Jun;20(3):308-10. doi: 10.1097/00000421-199706000-00021. Am J Clin Oncol. 1997. PMID: 9167760

3

A Phase I trial of calcitriol (1,25-dihydroxycholecalciferol) in patients with advanced malignancy.

Smith DC, Johnson CS, Freeman CC, Muindi J, Wilson JW, Trump DL. Smith DC, et al. Among authors: trump dl. Clin Cancer Res. 1999 Jun;5(6):1339-45. Clin Cancer Res. 1999. PMID: 10389917 Clinical Trial.

4

Phase I and pharmacokinetic study of vinblastine and high-dose megestrol acetate.

Matin K, Egorin MJ, Ballesteros MF, Smith DC, Lembersky B, Day RS, Johnson CS, Trump DL. Matin K, et al. Among authors: trump dl. Cancer Chemother Pharmacol. 2002 Sep;50(3):179-85. doi: 10.1007/s00280-002-0484-9. Epub 2002 Jul 19. Cancer Chemother Pharmacol. 2002. PMID: 12203099 Clinical Trial.

5

Modulation of O6-alkylguanine-DNA alkyltransferase-mediated carmustine resistance using streptozotocin: a phase I trial.

Panella TJ, Smith DC, Schold SC, Rogers MP, Winer EP, Fine RL, Crawford J, Herndon JE 2nd, Trump DL. Panella TJ, et al. Among authors: trump dl. Cancer Res. 1992 May 1;52(9):2456-9. Cancer Res. 1992. PMID: 1533174 Clinical Trial.

6

A phase I trial of high-dose oral tamoxifen and CHOPE.

Smith DC, Trump DL. Smith DC, et al. Among authors: trump dl. Cancer Chemother Pharmacol. 1995;36(1):65-8. doi: 10.1007/BF00685734. Cancer Chemother Pharmacol. 1995. PMID: 7720178 Clinical Trial.

7

A phase II trial of all-trans-retinoic acid in hormone-refractory prostate cancer: a clinical trial with detailed pharmacokinetic analysis.

Trump DL, Smith DC, Stiff D, Adedoyin A, Day R, Bahnson RR, Hofacker J, Branch RA. Trump DL, et al. Cancer Chemother Pharmacol. 1997;39(4):349-56. doi: 10.1007/s002800050582. Cancer Chemother Pharmacol. 1997. PMID: 9025776 Clinical Trial.

8

A phase II trial of CI-958 in patients with hormone-refractory prostate cancer.

Woolley PV, Freiha FS, Smith DC, Carlson L, Hofacker J, Quinn N, Grove W, Trump DL. Woolley PV, et al. Among authors: trump dl. Cancer Chemother Pharmacol. 1999;44(6):511-7. doi: 10.1007/s002800051126. Cancer Chemother Pharmacol. 1999. PMID: 10550573 Clinical Trial.

9

Determination of intermediate biomarker expression levels by quantitative reverse transcription-polymerase chain reaction in oral mucosa of cancer patients treated with liarozole.

Zeng Q, Smith DC, Suscovich TJ, Gooding WE, Trump DL, Grandis JR. Zeng Q, et al. Among authors: trump dl. Clin Cancer Res. 2000 Jun;6(6):2245-51. Clin Cancer Res. 2000. PMID: 10873074 Clinical Trial.

10

Phase II trial of oral 1,25-dihydroxyvitamin D (calcitriol) in hormone refractory prostate cancer.

Osborn JL, Schwartz GG, Smith DC, Bahnson R, Day R, Trump DL. Osborn JL, et al. Among authors: trump dl. Urol Oncol. 1995 Sep-Oct;1(5):195-8. doi: 10.1016/1078-1439(95)00061-5. Urol Oncol. 1995. PMID: 21224117 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

319 results

Search Page